World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
55
Citations
11151
World Ranking
15036
National Ranking
6293

Overview

Ezio Bonvini is affiliated with the Center for Biologics Evaluation and Research in the United States. Their primary field of study is Medicine, with a focus on Oncology, Immunology, Hematology, Radiology, Nuclear Medicine and Imaging, and Molecular Biology.

Their research encompasses a range of topics including:

  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • Acute Myeloid Leukemia Research
  • Monoclonal and Polyclonal Antibodies Research
  • Immunotherapy and Immune Responses
  • Immune Cell Function and Interaction
  • HER2/EGFR in Cancer Research

Some of their recent papers include:

  • "Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer," 2021, published in JAMA Oncology
  • "Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia," 2020, published in Blood
  • "Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer," 2020, published in Molecular Cancer Therapeutics
  • "Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial," 2022, published in Journal for ImmunoTherapy of Cancer
  • "Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule," 2020, published in Cell Reports Medicine

Frequent co-authors working alongside Ezio Bonvini include:

  • Paul A. Moore
  • Deryk Loo
  • Juniper A. Scribner
  • Thomas Son
  • James Tamura

Their publications commonly appear in several venues, indicating areas of recurring contribution:

  • Cancer Research (9 publications)
  • Blood (6 publications)
  • Molecular Cancer Therapeutics (3 publications)
  • Journal for ImmunoTherapy of Cancer (2 publications)
  • Journal of Clinical Oncology (2 publications)

Best Publications

  • CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.

    Robbie G. Majzner;Johanna L. Theruvath;Anandani Nellan;Sabine Heitzeneder

  • Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors

    Jeffrey B. Stavenhagen;Sergey Gorlatov;Nadine Tuaillon;Christopher T. Rankin

  • Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions

    Adam M. Boruchov;Glenn Heller;Maria-Concetta Veri;Ezio Bonvini

  • Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

    Paul A. Moore;Wenjun Zhang;G. Jonah Rainey;Steve Burke

  • Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

    Deryk Loo;Ralph F. Alderson;Francine Z. Chen;Ling Huang

  • Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells

    Kavita M. Dhodapkar;Jacob L. Kaufman;Marc Ehlers;Devi K. Banerjee

  • Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.

    Syd Johnson;Stephen Burke;Ling Huang;Sergey Gorlatov

  • Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.

    Hope S. Rugo;Seock Ah Im;Fatima Cardoso;Javier Cortés

  • Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

    Geoffrey L. Uy;Ibrahim Aldoss;Matthew C. Foster;Peter H. Sayre

  • Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

    Jeffrey L Nordstrom;Sergey Gorlatov;Wenjun Zhang;Yinhua Yang

  • dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats

    Victoriano Baladrón;María José Ruiz-Hidalgo;María Luisa Nueda;María José M. Díaz-Guerra

  • Monoclonal antibodies capable of discriminating the human inhibitory Fcγ-receptor IIB (CD32B) from the activating Fcγ-receptor IIA (CD32A): biochemical, biological and functional characterization

    Maria-Concetta Veri;Sergey Gorlatov;Hua Li;Steve Burke

  • Therapeutic Control of B Cell Activation via Recruitment of Fcγ Receptor IIb (CD32B) Inhibitory Function With a Novel Bispecific Antibody Scaffold

    Maria-Concetta Veri;Stephen Burke;Ling Huang;Hua Li

  • Notch-1 Controls the Expression of Fatty Acid-activated Transcription Factors and Is Required for Adipogenesis

    Carmen Garcés;M.J. Ruiz-Hidalgo;Jaime Font de Mora;Crystal Park

  • A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.

    Gurunadh R. Chichili;Ling Huang;Hua Li;Steve Burke

  • Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.

    Muneera Al-Hussaini;Michael P. Rettig;Julie K. Ritchey;Darja Karpova

  • Adipocyte differentiation is modulated by secreted delta-like (dlk) variants and requires the expression of membrane-associated dlk

    Carmen Garcés;María José Ruiz-Hidalgo;Ezio Bonvini;Julia Goldstein

  • CD32B, the human inhibitory Fc-γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma

    Christopher T. Rankin;Maria-Concetta Veri;Sergey Gorlatov;Nadine Tuaillon

  • Tumor Necrosis Factor {alpha} (TNF-{alpha}) Activates Jak1/Stat3-Stat5B Signaling through TNFR-1 in Human B Cells

    Sebastiano Miscia;Marco Marchisio;Alfredo Grilli;Valentina Di Valerio

  • KOVALENT BUNDNE DIABODIES, DER HAR IMMUNREAKTIVITET MED PD-1 OG LAG-3, OG FREMGANGSMÅDER TIL BRUG DERAF

    Bonvini Ezio;Johnson Leslie S;Shah Kalpana;Koenig Scott

Frequent Co-Authors

Scott Koenig
Scott Koenig MacroGenics (United States)
Paul A. Moore
Paul A. Moore MacroGenics (United States)
Syd Johnson
Syd Johnson AstraZeneca (United Kingdom)
Jon M. Wigginton
Jon M. Wigginton Bristol-Myers Squibb (Germany)
John F. DiPersio
John F. DiPersio Washington University in St. Louis
Ronald L. Wilder
Ronald L. Wilder National Institutes of Health
Douglas H. Smith
Douglas H. Smith University of Pennsylvania
Bob Löwenberg
Bob Löwenberg Erasmus MC
Fabio Ciceri
Fabio Ciceri Vita-Salute San Raffaele University
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Biology or Biochemistry opens doors to a wide variety of healthcare and science careers. Many students are now considering flexible online programs to begin or advance their education in related fields. For example, if you’re interested in diagnostic imaging and wish to enter healthcare quickly, online rad tech programs provide affordable and accessible options to earn an associate degree.

If nutrition and patient wellness interest you, pursuing one of the top dietitian masters programs can lead to a rewarding career as a registered dietitian. For those seeking entry-level roles in healthcare, there are medical assistant classes online with financial aid that offer flexible schedules and support for managing tuition costs.

Career advancement is also possible for certified medical assistants. Programs such as cma to lpn bridge programs online can help you transition toward licensed practical nursing, expanding your clinical responsibilities and earning potential. Whichever path you choose, online healthcare programs make it easier to match your studies to your career goals.

Best Scientists Citing Ezio Bonvini

Trending Scientists

Recently Published Articles